Lineage Cell Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate
Lineage Cell Therapeutics, Inc. (LCTX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 80.30% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-03-05
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2018-09-30 was 73.13%, a 23.68% increase year-over-year.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2018-03-31 was 56.09%, a 6.25% decline year-over-year.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2017-09-30 was 59.13%.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2017-03-31 was 59.83%.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2025 was 80.30%, a 5.38% increase from fiscal 2024.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 76.20%, a 2.01% increase from fiscal 2023.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2023 was 74.70%, a 1.36% increase from fiscal 2022.
- Lineage Cell Therapeutics, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2022 was 73.70%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month |
|---|---|---|---|---|
| 2025-12-31 | 80.30% 10-K · filed 2026-03-05 | |||
| 2024-12-31 | 76.20% 10-K · filed 2026-03-05 | |||
| 2023-12-31 | 74.70% 10-K · filed 2025-03-10 | |||
| 2023-09-30 | 74.70% 10-Q · filed 2023-11-09 | |||
| 2022-12-31 | 73.70% 10-K · filed 2024-03-07 | |||
| 2022-09-30 | 73.60% 10-Q · filed 2023-11-09 | |||
| 2018-09-30 | 73.13% 10-Q · filed 2018-11-08 | 66.23% 10-Q · filed 2018-11-08 | ||
| 2018-06-30 | 56.09% 10-Q · filed 2018-08-02 | |||
| 2018-03-31 | 56.09% 10-Q · filed 2018-05-10 | |||
| 2017-09-30 | 59.13% 10-Q · filed 2018-11-08 | 59.04% 10-Q · filed 2018-11-08 | ||
| 2017-06-30 | 59.80% 10-Q · filed 2018-08-02 | |||
| 2017-03-31 | 59.83% 10-Q · filed 2018-05-10 | |||
| 2014-12-31 | 83.20% 10-K · filed 2015-03-11 | |||
| 2013-12-31 | 95.22% 10-K · filed 2015-03-11 | |||
| 2012-12-31 | 98.88% 10-K · filed 2014-03-17 | |||
| 2011-12-31 | 106.49% 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |